For research & educational purposes only. This article is a neutral, procedural reference for laboratory / in-vitro research handling — not medical advice or a usage recommendation. These materials are not for human or animal consumption.
The short answer
ARA-290, also called cibinetide, is an 11-amino-acid peptide derived from one region of erythropoietin (EPO). It was engineered to engage the tissue-protective innate repair receptor without stimulating red blood cell production, which is what EPO itself does. BPC-157 is a 15-amino-acid partial sequence of a protein found in gastric juice. Its research describes several proposed pathways rather than one defined receptor.
| ARA-290 | BPC-157 | |
|---|---|---|
| Length | 11 amino acids | 15 amino acids |
| Derived from | Erythropoietin (helix B region) | A protein in human gastric juice |
| Target | Innate repair receptor (EPO receptor with CD131) | Several proposed pathways, no single receptor |
| Human data | Small published phase 2 trials | Very limited |
| Animal data | Moderate | Large |
Different design logic, different evidence shapes.
ARA-290: designed for one receptor
EPO acts on two receptor arrangements: one drives red blood cell production, the other, the innate repair receptor, is linked to tissue protection. ARA-290 was engineered from the part of EPO that engages the second without the first, so it is described as nonerythropoietic. Published research includes small human studies in small-nerve-fibre conditions and mechanistic work on pain signalling through the TRPV1 channel.
BPC-157: a large animal literature
BPC-157 has been studied extensively in rodent models of gut, tendon, muscle and wound injury, and the proposed mechanisms include blood-vessel growth signalling and the nitric oxide system. Recent systematic reviews make the same point consistently: the animal literature is large, and published human data is very limited.
Evidence quality
The two compounds are strong in opposite places. ARA-290 has a defined target and some published human data, from small trials. BPC-157 has volume, almost entirely from animal models. Neither has large human trials. A research design should cite each for what its literature actually covers.
Compounds referenced here are supplied as analytical-grade reference materials for in-vitro and laboratory research only. Nothing on this page is a recommendation for human or veterinary use.
Frequently asked questions
What is the difference between ARA-290 and BPC-157?
ARA-290 is an 11-amino-acid peptide engineered from erythropoietin to engage the innate repair receptor, with small published human trials. BPC-157 is a 15-amino-acid partial sequence of a gastric protein with a large animal literature and very little human data.
Is ARA-290 the same as EPO?
No. ARA-290 is a short peptide derived from one region of erythropoietin. It was engineered to engage the tissue-protective receptor without stimulating red blood cell production, which EPO does.
What is cibinetide?
Cibinetide is another name for ARA-290.
Does BPC-157 have human trials?
Published human data on BPC-157 is very limited. Systematic reviews describe its literature as predominantly animal studies.
Published research
A selection of peer-reviewed and clinical literature indexed on PubMed. Provided so qualified researchers can locate the primary sources — inclusion here is not a claim about any product or outcome.
- Human clinical trialMolecular medicine (Cambridge, Mass.) · 2013
ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density
View on PubMed - Human clinical trialMolecular medicine (Cambridge, Mass.) · 2015
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
View on PubMed - Peer-reviewed studyPeptides · 2016
ARA 290 relieves pathophysiological pain by targeting the TRPV1 channel
View on PubMed - Peer-reviewed studyPharmaceuticals (Basel, Switzerland) · 2025
BPC-157 peptide: medical applications — literature & patent review
View on PubMed - Peer-reviewed studyCell and tissue research · 2019
BPC-157 and musculoskeletal soft-tissue healing
View on PubMed - Systematic reviewHSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025
BPC-157 in orthopaedic sports medicine — systematic review
View on PubMed
Continue reading
- ARA-290: What It Is and What It DoesAn EPO-derived peptide stripped of its blood-building action, studied for nerve repair and inflammation.
- BPC-157: What It Is and What It DoesA repair signal copied from a stomach protein — studied for healing tendons, muscle, and the gut.
- KPV vs BPC-157: Inflammatory Signalling vs Tissue RepairBoth appear in gastrointestinal research, which is why they get compared. The pathways each is studied for are different.
- BPC-157 vs TB-500: Two Repair Peptides, Two Different MechanismsBoth appear in tissue-repair research, but one is a gastric-derived pentadecapeptide and the other a thymosin beta-4 fragment. Mechanism, evidence and handling compared.
VNG Research Team
VNG Labs supplies analytical-grade reference materials with lot-matched Certificates of Analysis. Our write-ups are neutral, source-cited references for qualified and independent researchers.
More from LearnResearch use only. Not for human consumption or veterinary use. Sold exclusively to qualified researchers for in vitro and laboratory research. These statements have not been evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Refrigerate upon receipt. Keep in dark environment.